Jian Qin (Michael) Yu, MD, FRCPC

Request an Appointment Online - Click Here New patients can request an appointment online or call

Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111-2497

PET scans are scheduled through the referring physician's office. Call 215-728-3883/2656.

Dr. Jian Qin (Michael) Yu


Chief, Nuclear Medicine

Clinical Expertise:

Positron Emission Tomography (PET) ; Scanning; Molecular Imaging; Novel tracers; Phase 0 trials; General Nuclear Medicine in Oncologic Applications;
Antibody imaging for kidney tumor


American Board of Nuclear Medicine;
The Royal College of Physicians and Surgeons of Canada, Fellow
Certification Board of Nuclear Cardiology;
Certified Clinical Densitometrist (CCD)

Medical Education

Beijing Medical University, Beijing, China, 1987


General Surgery, Beijing Medical University, Beijing, China;
Internal Medicine, MCP-Hahnemann University Hospital, Philadelphia, Pa;
Nuclear Medicine, MCP-Hahnemann University Hospital, Philadelphia, Pa.;
Nuclear Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pa.


PET, Hospital of the University of Pennsylvania, Philadelphia, Pa.;
Pediatric Nuclear Medicine, Children's Hospital of Philadelphia and Hospital of the University of Pennsylvania, Philadelphia, Pa.

Research Interests

Positron Emission Tomography (PET) Targeted Therapy, Hypoxia tracer, Angiogenesis tracer, Apoptosis tracer, novel tracer, early phase clinical trials.


Dr. Yu on My NCBI

  1. Yu JQ, Zhuang HM, Xiu Y, Talati E, Alavi A. Demonstration of Increased FDG Activity
    in Rosai-Dorfman Disease on Positron Emission Tomography.  Clinical Nuclear Medicine 29 (3): 209-210 MAR 2004 (PMID: 15162996)
  2. Yu JQ, Kumar R, Xiu Y, Alavi A, and Zhuang HM.  Diffuse FDG uptake in the lungs in
    patient with aspiration pneumonia on Positron Emission Tomographic imaging.  Clinical Nuclear Medicine 29 (9): 567-568 SEPT 2004 (PMID: 15311127)
  3. Yu JQ, Milestone BD, Parsons R, Doss M, Haas N: Findings of Intra-Mediastinal
    Gossypiboma with F-18 FDG PET in a Melanoma Patient.  Clinical Nuclear Medicine 33(5):344-345, May 2008 (PMID: 18431152)
  4. Doss M, Zhang JJ, Bélanger MJ, Stubbs JB, Hostetler EB, Alpaugh RK, Kolb H, Yu
    JQ: Biodistribution and Radiation Dosimetry of the Hypoxia Marker 18F–HX4 in monkeys and humans determined from whole-body PET/CT, Nuclear Medicine Communications 31(12): 1016-24; [Epub 2010 Oct 13]  (PMID: 20948452/NIHMSID#: 259162/PMCID: PMC3016990)
  5. Reddy S, Shaller CC, Doss M, Shchaveleva I, Yu JQ, Robinson MK: Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clinical Cancer Research, 2011 Mar.15; 17(6):1509-1520; [Epub 2010 Dec.21] (PMID: 21177408/PMCID: PMC3060271)
  6. Miller J, Doss M, McQuillen R, Shaller CC, Tolner B, Yu JQ, Chester K, Adams GP,
    Robinson MK: Impact of Expression System on the Function of the C6.5db PET
    Radiotracer, Tumor Biology, 2012; 33(3):617-27 [Epub 2012 March 1], PMID:
  7. Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig CJ, Yu JQ, Vallabhajosula S, Larson SM, Schoder H, English P, Neuberg DS, Martin P, Ely SA, Courtney R, Shaik N, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT and Shapiro GI: Selective CDK4/6 Inhibition with Tumor Responses by PD0332991 in Patients with Mantle Cell Lymphoma, Blood, 2012 119: 4597-4607 with editorial, [Epub 2012 March 1], PMID: 22383795
  8. Doss M, Kolb HC, Zhang JJ, Bélanger M, Stubbs JB, Stabin MG, Hostetler ED, Alpaugh
    RK, von Mehren M, Walsh JC, Haka M, Mocharla VP, Yu JQ*: Biodistribution and Radiation Dosimetry of the Integrin Marker 18F-RGD-K5 in monkeys and humans determined from whole-body PET/CT, Journal of Nuclear Medicine 2012; 53:787-795 [Epub 2012 Apr 12], PMID: 22499613
  9. Divgi C, Uzzo R, Gatsonis C, Bartz R, Treutner S, Yu JQ, Chen D, Carrasquillo J, Larson S, Bevan P, Russo P:   PET/CT Identification of Clear Cell Renal Cell Carcinoma: Results of the REDECT Trial. Journal of Clinical Oncology, January 10, 2013: vol. 31, no. 2, 187-194. [Epub Dec. 3, 2012], PMID: 23213092
  10. Lango M, Flieder D, Arrangoiz R, Veloski C, Yu JQ, Li T, Burtness B, Mehra R,
    Galloway T, Ridge J: Extranodal extension of Metastatic Papillary Thyroid Carcinoma: Correlation with biochemical endpoints, nodal persistence and systemic disease progression. Thyroid, 23(9), 1099-1105 [Epub Feb. 19, 2013], PMID: 23421588/PMCID: PMC3770240